All In Biotech

Drug Trial Radar · NCT07756580

A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines

A Phase 1 Study to Evaluate the Safety and Efficacy of Sequential Administration of AGN-151586 and BOTOX® in Subjects for Treatment of Glabellar Lines (GL)

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 143 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

143

Actual

Start

Aug 10, 2026

Primary completion

Feb 2027

Study completion Mar 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Aug 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. The purpose of this study is to assess how safe and effective sequential administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) is in adult participants with moderate to severe GL. AGN-151586 is an investigational drug being developed for treatment of moderate to severe glabellar lines. Participants are placed into 1 of 2 groups called treatment arms. In both arms participants will receive both AGN-151586 and BOTOX. Approximately 120 adult participants with moderate to severe glabellar lines enrolled in the study in approximately 8 sites around the United States. Participants will receive injections of AGN-151586 on Day 1 in the glabellar complex. After meeting treatment criteria, participants in Cohort 1 will receive intramuscular injections of BOTOX on Day 14, and participants in Cohort 2 will receive intramuscular injections of BOTOX on Day 21. Participants will be followed for up to approximately 141 days.

Conditions

  • Glabellar Lines

Interventions

  • AGN-151586Drug

    Injection

  • BOTOXDrug

    Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately Day 141

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Advanced Research Associates - Glendale /ID# 283833

    Glendale, Arizona

  • Eye Research Foundation /ID# 283835

    Newport Beach, California

  • Pacific Clinical Innovations /ID# 283812

    Vista, California

  • Etre, Cosmetic Dermatology And Laser Center /ID# 283831

    New Orleans, Louisiana

  • Skincare Physicians /ID# 283851

    Chestnut Hill, Massachusetts

  • Wilmington Dermatology Center /ID# 283853

    Wilmington, North Carolina

  • Tennessee Clinical Research Center /ID# 283894

    Nashville, Tennessee

  • Austin Institute for Clinical Research - Pflugerville /ID# 283817

    Pflugerville, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.